Posted on 16 February 2015
Actavis will divest to TPG the pharma business currently known as Aptalis Pharmaceutical Technologies (Pharmatech) a pharmaceutical outsourcing and R&D business within Actavis' subsidiary Aptalis operating in the United States, Canada and Europe.
No other Aptalis pharma business or products are included in the transaction.
No financial terms were disclosed.
By acquiring Pharmatech TPG intends to use the company as a platform to enter into new partnerships and make additional acquisitions to grow the business.
|Searching for more deal information? Current Partnering offers the following options:
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
Scorecard: Top partnering deals by value in 2015
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio